Activated protein C resistance among postmenopausal women using transdermal estrogens: Importance of progestogen

Menopause

Volumn 17, Issue 6, 2010, Pages 1122-1127

  Canonico, Marianne ^a,b   Alhenc Gelas, Martine ^c   Plu Bureau, Geneviève ^a,d,e   Olié, Valérie ^a,b   Scarabin, Pierre Yves ^a,b  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔTEL DIEU   (France)

Author keywords

Activated protein C resistance; Hemostasis; Postmenopausal hormone therapy; Progestogens

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; ESTRADIOL; GENOMIC DNA; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NOMEGESTROL ACETATE; PROGESTERONE; PROMEGESTONE; PROTHROMBIN; PROTHROMBIN ACTIVATION PEPTIDE; THROMBIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG ADMINISTRATION ROUTE; DRUG INDUCED DISEASE; FEMALE; HEMOSTASIS; HORMONAL THERAPY; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; NORMAL HUMAN; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RISK FACTOR; THROMBOGENESIS; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADMINISTRATION, CUTANEOUS; AGED; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HEMOSTASIS; HUMANS; LINEAR MODELS; MIDDLE AGED; NORPREGNANES; PEPTIDE FRAGMENTS; POSTMENOPAUSE; PROGESTINS; PROTHROMBIN; THROMBIN;

EID: 78649649692     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e102eb     Document Type: Article

References (38)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
3. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-1231.
4. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembo-lism risk. Lancet 2003;362:428-432.
5. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845.
6. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-345.
7. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
8. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-1276.
9. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-3078.
10. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-1676.
11. Post MS, Christella M, Thomassen LG, et al. Effect of oral and trans-dermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in post-menopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-1121.
12. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003;33:4-15.
13. Alhenc-Gelas M, Arnaud E, Nicaud V, et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 1999;81:506-510.
14. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the Women's International Study of Long Duration Oestrogen After Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239.
15. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580.
16. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-780.
17. Tans G, van Hylckama Vlieg A, Thomassen MC, et al. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122: 465-470.
18. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive proteinVa cross-sectional population survey. Thromb Haemost 2001; 86:550-556.
19. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in post-menopausal women. Thromb Haemost 2001;85:619-625.
20. Zegura B, Keber I, Sebestjen M, Koenig W. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. Atherosclerosis 2003;168:123-129. (Pubitemid 36555819)
21. Martinez C, Basurto L, Zarate A, Saucedo R, Gaminio E, Collazo J. Transdermal estradiol does not impair hemostatic biomarkers in post-menopausal women. Maturitas 2005;50:39-43.
22. Callejon DR, Franceschini SA, Montes MB, Toloi MR. Hormone replacement therapy and hemostasis: effects in Brazilian postmenopausal women. Maturitas 2005;52:249-255.
23. Perrone G, Capri O, Galoppi P, et al. Effects of either tibolone or continuous combined transdermal estradiol with medroxyprogesterone acetate on coagulatory factors and lipoprotein(a) in menopause. Gynecol Obstet Invest 2009;68:33-39.
24. Bonduki CE, Lourenco DM, Motta EL, Soares JM Jr, Haidar MA, Baracat EC. Effect of estrogen-progestin hormonal replacement therapy on blood coagulation and fibrinolysis in postmenopausal women. Clinics (Sao Paulo) 2007;62:553-560.
25. Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers. Br J Haematol 2004;124:802-808.
26. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007;97:558-565.
27. Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmeno-pausal women. Arterioscler Thromb Vasc Biol 2006;26:1660-1666.
28. Conard J, Basdevant A, Thomas JL, et al. Cardiovascular risk factors and combined estrogen-progestin replacement therapy: a placebo-controlled study with nomegestrol acetate and estradiol. Fertil Steril 1995;64:957-962.
29. van Baal WM, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CD. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Haemost 2000;83:29-34.
30. Post MS, Hendriks DF, Van Der Mooren MJ, et al. Oral oestradiol/ trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women. J Intern Med 2002;251:245-251.
31. Norris LA, Brosnan J, Bonnar J, Conard J, Kluft C, Hellgren M. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/dydrogesterone and estradiol (2 mg)/trimegestone. Thromb Haemost 2008;100:253-260.
32. Hoibraaten E, Mowinckel MC, de Ronde H, Bertina RM, Sandset PM. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. Br J Haematol 2001;115:415-420.
33. Marque V, Alhenc-Gelas M, Plu-Bureau G, Oger E, Scarabin PY. The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women. Thromb Haemost 2001; 86:713-714.
34. Regan LM, Stearns-Kurosawa DJ, Kurosawa S, Mollica J, Fukudome K, Esmon CT. The endothelial cell protein C receptor. Inhibition of activated protein C anticoagulant function without modulation of reaction with proteinase inhibitors. J Biol Chem 1996;271:17499-17503.
35. Plu-Bureau G, Le MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P. Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 1994; 70:270-277.
36. Sitruk-Ware R. New progestogens: a review of their effects in perimeno-pausal and postmenopausal women. Drugs Aging 2004;21:865-883.
37. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8:3-63.
38. Simon T, Beau Yon de Jonage-Canonico M, Oger E, et al. Indicators of lifetime endogenous estrogen exposure and risk of venous thromboem-bolism. J Thromb Haemost 2006;4:71-76.